<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-141559" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hereditary Hemorrhagic Telangiectasia (HHT)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Locke</surname>
            <given-names>Tran</given-names>
          </name>
          <aff>Baylor College of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gollamudi</surname>
            <given-names>Jahnavi</given-names>
          </name>
          <aff>Baylor College of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chen</surname>
            <given-names>Philip</given-names>
          </name>
          <aff>University of Texas Health San Antonio</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tran Locke declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jahnavi Gollamudi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Philip Chen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>12</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-141559.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hereditary hemorrhagic telangiectasias (HHT) is an autosomal dominant bleeding disorder caused by malformed vessels. The condition manifests as telangiectasias affecting the skin and mucosa and arteriovenous malformations involving organs like the lung, brain, and liver. This activity reviews the pathophysiology of the disease and emphasizes the importance of an interprofessional team&#x02019;s approach to evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;the pertinent history and physical exam findings associated with HHT and additional tests to diagnose the condition.</p></list-item><list-item><p>Assess&#x000a0;the pathophysiology of HHT and its clinical manifestations.</p></list-item><list-item><p>Differentiate the&#x000a0;medical treatment options that are available for HHT.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=141559&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=141559">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-141559.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Hereditary hemorrhagic telangiectasia (HHT), formerly Osler-Weber-Rendu, is an inherited (autosomal dominant) disease that results in malformed blood vessels (see <bold>Image.</bold> Telangiectasia on the Tongue). The disease is named after the physicians who first independently described the condition: Henri Jules Louis Marie Rendu in 1896, William Osler in 1901, and Frederick Parkes Weber in 1907.<xref ref-type="bibr" rid="article-141559.r1">[1]</xref>&#x000a0;The malformations typically manifest as mucocutaneous telangiectasias and visceral arteriovenous malformations (AVMs).<xref ref-type="bibr" rid="article-141559.r2">[2]</xref>&#x000a0;These vascular malformations are responsible for much of the clinical bleeding associated with this disease, ranging from mild epistaxis to life-threatening intracranial bleeds.<xref ref-type="bibr" rid="article-141559.r3">[3]</xref><xref ref-type="bibr" rid="article-141559.r4">[4]</xref><xref ref-type="bibr" rid="article-141559.r5">[5]</xref>&#x000a0;Some patients with HHT develop pulmonary hypertension, a prothrombotic state, or immune dysfunction.<xref ref-type="bibr" rid="article-141559.r6">[6]</xref>&#x000a0;The earliest clinical sign of HHT, often occurring by the second decade of life, is recurrent epistaxis. Telangiectasias, which are dilated blood vessels, are frequently present on the skin and buccal mucosa in the third decade of life.&#x000a0;The number of telangiectasias increases with age, accompanied by increased frequency of epistaxis or gastrointestinal (GI) bleeds, leading to anemia, poorer quality of life, and increased healthcare resource utilization, including iron or blood transfusions and hospitalizations.<xref ref-type="bibr" rid="article-141559.r7">[7]</xref></p>
      </sec>
      <sec id="article-141559.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Genes comprise DNA, which encodes for distinct proteins that perform a specific function in the body. Through transcription, the DNA is converted into messenger RNA (mRNA) and then translated into a protein. HHT is an autosomal dominant disorder affecting blood vessels within multiple organ systems. The condition is suspected of haploinsufficiency, where&#x000a0;1 functional gene copy cannot produce the required protein to preserve function.<xref ref-type="bibr" rid="article-141559.r2">[2]</xref>&#x000a0;In 97% of patients with a definite clinical HHT diagnosis, a causative mutation is identified in&#x000a0;1 of&#x000a0;3 genes described below.<xref ref-type="bibr" rid="article-141559.r8">[8]</xref>&#x000a0;These mutations disrupt signaling by transforming growth factor-beta (TGF-B), essential for maintaining vascular integrity.<xref ref-type="bibr" rid="article-141559.r9">[9]</xref><xref ref-type="bibr" rid="article-141559.r10">[10]</xref><xref ref-type="bibr" rid="article-141559.r11">[11]</xref></p>
        <p>
<bold>HHT Type I (HHT1)</bold>
</p>
        <p>HHT1 stems from mutations in the gene ENG, which codes for endoglin on chromosome 9.<xref ref-type="bibr" rid="article-141559.r12">[12]</xref>&#x000a0;Endoglin is a membrane glycoprotein part of the tumor growth factor-beta (TGF-B) receptor complex needed for vascular integrity.</p>
        <p>
<bold>HHT Type 2 (HHT2)</bold>
</p>
        <p>HHT2 results from Activin A receptor-like type I (ACVRL1) mutations, which codes for the protein activin receptor-like kinase 1 (ALK1) on chromosome 12.<xref ref-type="bibr" rid="article-141559.r13">[13]</xref>&#x000a0;ALK1 is a type 1 cell-surface receptor for the TGF-B superfamily and is found on the surface of cells, particularly on the lining of developing arteries.<xref ref-type="bibr" rid="article-141559.r14">[14]</xref></p>
        <p>
<bold>HHT Associated with Juvenile Polyposis (JPHT or JP-HHT)</bold>
</p>
        <p>JPHT is due to a mutation in the gene Mothers Against Decapentaplegic homolog 4 (MADH4) that codes for the transcription factor SMAD4, a critical downstream effector of TGF-B signaling.<xref ref-type="bibr" rid="article-141559.r15">[15]</xref>&#x000a0;The mutations in JPHT are located on the last&#x000a0;4 exons of <italic toggle="yes">Smad4</italic> and include several mutation types, including nonsense, missense, frameshift, and <italic toggle="yes">de novo</italic>.<xref ref-type="bibr" rid="article-141559.r6">[6]</xref>&#x000a0;The distribution in gene mutations among HHT patients is predominantly ENG (61%), followed by ACVRL1 (37%), and then MADH4 (2%). Over 600 mutations, including deletions, missense, nonsense, and insertions, have also been identified in ENG or ACVR genes.</p>
      </sec>
      <sec id="article-141559.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>HHT affects 1 in 5,000-8,000 individuals and can affect both genders and people of all races.<xref ref-type="bibr" rid="article-141559.r2">[2]</xref><xref ref-type="bibr" rid="article-141559.r5">[5]</xref><xref ref-type="bibr" rid="article-141559.r6">[6]</xref><xref ref-type="bibr" rid="article-141559.r7">[7]</xref>&#x000a0;Some studies have noted a higher incidence in women, although this gender difference may be attributed to access to healthcare resources.<xref ref-type="bibr" rid="article-141559.r16">[16]</xref><xref ref-type="bibr" rid="article-141559.r17">[17]</xref></p>
      </sec>
      <sec id="article-141559.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Pathogenesis of HHT is primarily due to the gene mutations (endoglin, ACVRL1, and SMAD4) that affect the endothelial cell receptors of the TGF-B superfamily. A mutation in these receptors prevents downstream signaling and disrupts angiogenesis, promoting a disorganized cytoskeleton and dysfunctional remodeling of the vascular endothelium. As a result, these vessels&#x000a0;lose elasticity and remain chronically dilated.<xref ref-type="bibr" rid="article-141559.r18">[18]</xref>&#x000a0;The loss of vascular integrity, combined with constant pressure, results in telangiectasias (dilated microvessels) and large AVMs.<xref ref-type="bibr" rid="article-141559.r19">[19]</xref><xref ref-type="bibr" rid="article-141559.r9">[9]</xref>&#x000a0;Due to the vessel walls' decreased elasticity and vascular lumen dilation, telangiectasias are fragile and more prone to hemorrhage.&#x000a0;AVMs can form in the brain, lungs, GI tract, spine, or liver.<xref ref-type="bibr" rid="article-141559.r19">[19]</xref>&#x000a0;Up to 10% of HHT patients have cerebral AVMs, 15 to 45% develop pulmonary AVMs, and 75% have hepatic AVMs. Rupture of these AVMs can result in severe complications, including internal hemorrhage, embolic or hemorrhagic stroke, seizures, migraines, or brain abscesses.<xref ref-type="bibr" rid="article-141559.r17">[17]</xref>&#x000a0;Untreated pulmonary and hepatic AVMs can lead to arteriovenous shunting and pulmonary hypertension.<xref ref-type="bibr" rid="article-141559.r6">[6]</xref>. There are phenotypic variations between HHT1 and HHT2. HHT1 patients develop epistaxis earlier in life and have pulmonary AVMs, while HHT2 patients are likelier to develop hepatic AVMs.<xref ref-type="bibr" rid="article-141559.r20">[20]</xref></p>
      </sec>
      <sec id="article-141559.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Normally, arteries and veins are connected by an intermediary capillary system. AVMs and telangiectasias lack this intermediary, with a direct connection between the artery and the vein.&#x000a0;Telangiectasias occur on mucocutaneous surfaces, while AVMs are found within internal organs. Histological evaluation of AVMs shows irregular endothelium, increased collagen and actin deposition in the basement membrane, and a disorganized basement membrane.<xref ref-type="bibr" rid="article-141559.r21">[21]</xref></p>
      </sec>
      <sec id="article-141559.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Although autosomal dominant, the clinical manifestations of HHT are variable, even within families.<xref ref-type="bibr" rid="article-141559.r6">[6]</xref>&#x000a0;The classic triad consists of epistaxis, telangiectasias, and positive family history of similarly affected individuals.</p>
        <p>
<bold>Epistaxis</bold>
</p>
        <p>The earliest clinical manifestation and primary complaint in up to 96% of patients are spontaneous, recurrent epistaxis stemming from nasal mucosal telangiectasias.&#x000a0;Epistaxis can occur as early as childhood and increases in prevalence with age, potentially resulting in anemia and the need for blood or iron transfusions. The average age of epistaxis onset is 12 years, with almost 100% of HHT patients affected by 40 years and an average of 18 monthly bleeds.<xref ref-type="bibr" rid="article-141559.r22">[22]</xref><xref ref-type="bibr" rid="article-141559.r23">[23]</xref>&#x000a0;Evaluation of epistaxis should involve anterior rhinoscopy of the nasal cavity. If resources are available, nasal endoscopy&#x000a0;or&#x000a0;upper airway endoscopy with a rigid or flexible fiberoptic scope can be done to evaluate for the presence of telangiectasias in the nasal or oral mucosa&#x000a0;(see <bold>Image.</bold>&#x000a0;Telangiectasia in Nasal Cavity). However, great care needs to be taken to avoid unnecessary bleeding.</p>
        <p>
<bold>Mucocutaneous Telangiectasias</bold>
</p>
        <p>Telangiectasias of the skin and oral mucosa appear around the 3rd decade and increase in number and frequency with age.<xref ref-type="bibr" rid="article-141559.r6">[6]</xref>&#x000a0;Recurrent GI bleeds manifest later in 15-20% of HHT patients.<xref ref-type="bibr" rid="article-141559.r7">[7]</xref>&#x000a0;Patients should be queried about bleeding frequency and severity. On physical exam, HHT patients have telangiectasias involving the nasal mucosa, oral cavity including hard palate, tongue, and lips, as well as cutaneous lesions on the fingers and nose (see <bold>Images.</bold>&#x000a0;HHT Telangiectasias on Thumb, Lip Telangiectasia).<xref ref-type="bibr" rid="article-141559.r9">[9]</xref></p>
        <p>
<bold>Cutaneous Telangiectasias on the Fingers</bold>
</p>
        <p>
<bold>Visceral Arteriovenous Malformations (AVM)</bold>
</p>
        <p>Patients may also develop AVMs of the lungs, GI tract, brain, liver, or spine. AVM-related symptoms and complications should be assessed, including a history of stroke, heart failure, venous thromboembolism, iron deficiency, brain abscesses, arteriovenous shunting, liver disease, migraines, and pulmonary hypertension.<xref ref-type="bibr" rid="article-141559.r19">[19]</xref>&#x000a0;Cerebral and pulmonary AVMs typically form perinatally and pre-puberty, respectively.<xref ref-type="bibr" rid="article-141559.r24">[24]</xref>&#x000a0;In addition, because patients with the JPHT form are at higher odds of developing colon cancer, patients should be queried for signs or symptoms of colorectal cancer, such as weight loss, change in bowel habits, and history of colorectal cancer among affected family members. On exam, patients may present with hepatomegaly or hepatic bruits due to the left-to-right shunting of blood in hepatic AVMs.<xref ref-type="bibr" rid="article-141559.r25">[25]</xref>&#x000a0;Additionally, patients may exhibit pallor due to chronic anemia.</p>
        <p>
<bold>Family History</bold>
</p>
        <p>In patients with a positive family history of HHT, the presence of a visceral AVM essentially confirms the diagnosis since AVMs are rare in the general population.&#x000a0;For unaffected patients with a parent with HHT, the disease cannot be ruled out due to variable age-related onset of signs and symptoms. European studies on HHT patients estimate the probability of clinical HHT in patients with an affected family member to range from 0.5, 0.22, and 0.01 at 0-, 16-, and 60 years.<xref ref-type="bibr" rid="article-141559.r7">[7]</xref><xref ref-type="bibr" rid="article-141559.r26">[26]</xref></p>
        <p>
<bold>Classification Criteria</bold>
</p>
        <p>The diagnosis of HHT has relied on Cura&#x000e7;ao Criteria, which encompasses the classic features of the disease: 1) spontaneous, recurrent epistaxis, 2) positive family history, 3) cutaneous or mucosal telangiectasias, and 4) visceral lesions. A definitive diagnosis is made if patients have 3 of the 4 criteria, and a possible or suspected diagnosis is made if patients meet 2 of the 4 criteria.<xref ref-type="bibr" rid="article-141559.r5">[5]</xref>&#x000a0;Of note is that the criteria have a poor negative predictive value in children under the age of 16 years.<xref ref-type="bibr" rid="article-141559.r27">[27]</xref></p>
      </sec>
      <sec id="article-141559.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>Genetic Testing</bold>
</p>
        <p>Genetic mutation testing should be done to confirm a diagnosis of HHT, including patients who meet 1-2 of the Cura&#x000e7;ao criteria or young children with affected parents who are yet to develop the clinical manifestations.<xref ref-type="bibr" rid="article-141559.r19">[19]</xref>&#x000a0;Initial genetic testing should screen for the&#x000a0;3 most prevalent mutations: ENG, ACVRL1, and SMAD4. Testing should also be extended to family members. It is important to note that genetic mutations are not identified in up to 10 to 15% of HHT families, and a negative genetic test does not exclude the diagnosis of HHT. Once the diagnosis is confirmed, additional tests can be done to evaluate for other HHT manifestations. Screening should be done, regardless of a patient&#x02019;s clinical symptoms, due to the danger of undiagnosed silent AVMs.&#x000a0;</p>
        <p>
<bold>Ancillary Tests for Visceral AVMs</bold>
</p>
        <p>Pulmonary AVMs are often silent but can lead to strokes, massive hemoptysis, spontaneous hemothorax, transient ischemic attacks, and brain abscesses.<xref ref-type="bibr" rid="article-141559.r22">[22]</xref>&#x000a0;Sensitive screening tests to detect pulmonary AVMs include thoracic CT scan and transthoracic contrast/bubble echocardiography; both modalities can also detect pulmonary hypertension. Most screening protocols use contrast echocardiography as a first-line test, followed by a thoracic CT to determine the anatomic location and if embolization is viable. Chest X-rays, right-to-left shunt measurements, and blood oxygen measurements are less sensitive to identifying the presence of pulmonary AVMs.</p>
        <p>Multiple cerebral AVMs are predictive of HHT.<xref ref-type="bibr" rid="article-141559.r28">[28]</xref>&#x000a0;The role of screening remains controversial due to the overall low risk, albeit significant morbidity or mortality, of hemorrhage. Additionally, the risks associated with treating asymptomatic cerebral AVMs potentially outweigh the benefits.&#x000a0;An MRI brain with and without contrast is initially recommended for patients with cerebral symptoms, who have a known unstable cerebral aneurysm, or a family member who has had a cerebral hemorrhage since familial aneurysms have a higher risk of hemorrhage.<xref ref-type="bibr" rid="article-141559.r29">[29]</xref>&#x000a0;The gold standard for diagnosing and treating cerebral AVMs is diagnostic angiography, which carries a 0.5% risk of stroke.<xref ref-type="bibr" rid="article-141559.r25">[25]</xref></p>
        <p>Routine gastrointestinal (GI) endoscopy is not typically performed. However, patients with anemia disproportionate to the severity of epistaxis or with a history of GI bleeding should undergo an esophagogastroduodenoscopy (EGD) to detect and treat GI AVMs.<xref ref-type="bibr" rid="article-141559.r9">[9]</xref><xref ref-type="bibr" rid="article-141559.r22">[22]</xref>&#x000a0;If EGD is inconclusive, capsule endoscopy can be considered. Additionally, patients with the JPHT form of HHT should have a screening colonoscopy starting at the age of 15 due to a higher risk of colon cancer. This should be repeated every&#x000a0;3 years if no colon polyps are found. If polyps are detected, the patient should undergo yearly EGD and colonoscopy.<xref ref-type="bibr" rid="article-141559.r22">[22]</xref>&#x000a0;Screening for asymptomatic hepatic AVMs with Doppler ultrasonography is recommended because it is non-invasive and can improve patient management and outcomes. While Doppler ultrasonography is ideal due to its accuracy, cost, safety, and tolerability, depending on resources available and operator expertise, patients can be screened by alternate means, such as multiphase contrast CT or MRI.<xref ref-type="bibr" rid="article-141559.r19">[19]</xref><xref ref-type="bibr" rid="article-141559.r6">[6]</xref></p>
        <p>
<bold>Laboratory Evaluation</bold>
</p>
        <p>Laboratory testing should be done before all surgical interventions, including a complete blood count and a type and screen or type and crossmatch.<xref ref-type="bibr" rid="article-141559.r9">[9]</xref>&#x000a0;Furthermore, all adults, regardless of symptoms and children with recurrent bleeding, should have annual complete blood count and ferritin levels measured to screen for iron deficiency anemia. If the patient is anemic but ferritin is normal, further workup with serum iron, transferrin saturation, and total iron-binding capacity should be performed.<xref ref-type="bibr" rid="article-141559.r19">[19]</xref><xref ref-type="bibr" rid="article-141559.r22">[22]</xref>&#x000a0;HHT patients with severe epistaxis demonstrate microcytic iron deficiency anemia with low ferritin and elevated transferrin.<xref ref-type="bibr" rid="article-141559.r9">[9]</xref> &#x000a0;</p>
        <p>
<bold>Pregnancy</bold>
</p>
        <p>Pregnant women with HHT should have access to a multidisciplinary maternal-fetal team with knowledge of HHT, and pre-conception and prenatal diagnostic options should be discussed. Asymptomatic pregnant women should have an agitated saline transthoracic contrast echocardiography (TTCE) or a diagnostic low-dose chest CT without contrast for pulmonary AVMs. Any intervention should be delayed until the 2nd trimester.<xref ref-type="bibr" rid="article-141559.r22">[22]</xref>&#x000a0;Spinal AVMs can be detected with a spinal MRI and can be considered in pregnant women, particularly if epidural anesthesia is considered.<xref ref-type="bibr" rid="article-141559.r6">[6]</xref>&#x000a0;However, an expert consensus panel recommended against withholding an epidural, as risks of complications are unsubstantiated.&#x000a0;Pregnant women with symptomatic cerebral AVMs or previous cerebral hemorrhage should have an unenhanced MRI in the second trimester. For asymptomatic cerebral AVMs, vaginal delivery may be attempted. However, for HHT patients with symptomatic cerebral AVMs or prior hemorrhage, a cesarean section should be considered to avoid the strain associated with delivering vaginally.<xref ref-type="bibr" rid="article-141559.r22">[22]</xref></p>
      </sec>
      <sec id="article-141559.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment options are tailored to the patient, and the best approach is based on local versus systemic measures. Due to the few randomized trials, there are no standard therapies for HHT. Management of HHT focuses on supportive care, preventing complications, and reducing symptom severity.</p>
        <p>
<bold>Epistaxis</bold>
</p>
        <p>Epistaxis prevention is the primary goal for HHT-related nosebleeds. Preventative measures include topical moisturizers and emollients, nasal hygiene with humidifiers and saline irrigations, and avoiding triggers and blood thinners.<xref ref-type="bibr" rid="article-141559.r30">[30]</xref><xref ref-type="bibr" rid="article-141559.r19">[19]</xref>&#x000a0;Conservative management of ongoing epistaxis includes topical decongestant spray, manual pressure, absorbable nasal packing, and chemical cauterization with silver nitrate.<xref ref-type="bibr" rid="article-141559.r9">[9]</xref>&#x000a0;Non-dissolvable nasal packing should be avoided due to the risk of increased mucosal trauma with insertion and removal of the packing. Epistaxis refractory to conservative measures may require surgical or endovascular interventions.<xref ref-type="bibr" rid="article-141559.r19">[19]</xref>&#x000a0;Other medical interventions targeting the molecular biology of the disease have been used &#x02013; many of which have gained and lost favor. These medical treatments aim to reduce nosebleeds' frequency, volume, and severity and improve quality of life. These topical and oral agents include estrogen agents (tamoxifen, raloxifene, and estriol ointment), tranexamic acid, thalidomide, beta-blockers (timolol or propranolol), and vascular endothelial growth factor (VEGF) inhibitors (bevacizumab).<xref ref-type="bibr" rid="article-141559.r9">[9]</xref><xref ref-type="bibr" rid="article-141559.r31">[31]</xref>&#x000a0;Oral tranexamic acid is a possible option for treating HHT-epistaxis refractory to moisturizing topical therapies.<xref ref-type="bibr" rid="article-141559.r32">[32]</xref>&#x000a0;Two randomized control trials evaluating oral tranexamic acid for HHT-related epistaxis demonstrated a 17.3% reduction in epistaxis duration and a 54% reduction in epistaxis intensity.<xref ref-type="bibr" rid="article-141559.r33">[33]</xref><xref ref-type="bibr" rid="article-141559.r34">[34]</xref></p>
        <p>Surgical interventions focused on prevention and reducing severity include electrosurgical plasma coagulation, potassium titanyl phosphate (KTP) laser photocoagulation, and sclerotherapy with sodium tetradecyl sulfate.<xref ref-type="bibr" rid="article-141559.r35">[35]</xref>&#x000a0;Laser photocoagulation improves the quality of life outcomes and decreases the frequency and severity of epistaxis.&#x000a0;Other surgical interventions for moderate to severe epistaxis include septodermoplasty and Young&#x02019;s procedure. Septodermoplasty involves removing the sinonasal mucosal and replacement with a split-thickness skin graft.<xref ref-type="bibr" rid="article-141559.r36">[36]</xref>&#x000a0;After the surgery, epistaxis is reduced for at least&#x000a0;2 years, though the problem typically recurs with time as telangiectasias affect the graft.&#x000a0;This procedure has lost favor among many. Young&#x02019;s technically reversible procedure involves the closure of&#x000a0;1 or both nostrils using mucocutaneous flaps, resulting in complete obstruction of airflow through the nose and resolution of epistaxis.<xref ref-type="bibr" rid="article-141559.r37">[37]</xref>&#x000a0;After Young&#x02019;s procedure, patients suffer hyposmia and hypogeusia but also have complete cessation of epistaxis. This procedure is reserved for severe, life-threatening epistaxis and is relatively uncommon.</p>
        <p>
<bold>Anemia and Anticoagulation</bold>
</p>
        <p>All patients with iron deficiency and anemia require iron replacement, either orally or intravenously, if the oral form is not absorbed or well-tolerated. Oral replacement starts with 35&#x000a0;to 65 mg of elemental iron daily, taken 2 hours prior or 1 hour after meals. IV iron infusions may be required regularly, starting at 1 gm in a single dose or divided infusions for refractory or severe anemia.<xref ref-type="bibr" rid="article-141559.r38">[38]</xref>&#x000a0;Blood transfusions should be considered in the following situations: hemodynamic shock, comorbidities requiring a higher hemoglobin baseline before surgery or pregnancy, or inadequate hemoglobin levels despite iron transfusions. Anticoagulation is permissible in HHT patients.<xref ref-type="bibr" rid="article-141559.r39">[39]</xref>&#x000a0;Vitamin K antagonists and unfractionated and low-molecular-weight heparins are preferred and better than direct-acting oral anticoagulants (DOACs).&#x000a0;Currently, there is more literature regarding tolerance with heparin and warfarin in HHT patients. Warfarin is the oral anticoagulant of choice because of its tolerance and the existence of a reversal agent. Finally, a small retrospective study evaluating DOAC showed increased HHT-related epistaxis while on DOACs.<xref ref-type="bibr" rid="article-141559.r40">[40]</xref>&#x000a0;If dual therapy is required, the duration of treatment should be minimized, and patients should be closely observed.</p>
        <p>
<bold>GI Bleeding</bold>
</p>
        <p>Patients with mild to moderate HHT-related GI bleeding can be managed with iron replacement. For severe cases, hemoglobin can be managed with scheduled iron replacement and transfusions. For patients with moderate to severe GI bleeding refractory to iron replacement and transfusions, there is moderate evidence for intravenous bevacizumab or other systemic antiangiogenic therapy and inadequate evidence for oral antifibrinolytics. Endoscopic argon plasma coagulation is an option to address bleeding and non-bleeding lesions during upper GI endoscopy; however, the evidence for this is low.<xref ref-type="bibr" rid="article-141559.r22">[22]</xref></p>
        <p>
<bold>Pulmonary AVMs (PAVMs)</bold>
</p>
        <p>Detection and treatment of asymptomatic PAVM are recommended due to associated neurological risks, including brain abscesses and paradoxical embolic strokes.&#x000a0;The mainstay treatment of PAVMs is transcatheter embolization with embolic material such as metallic coils and Amplatzer vascular plugs.<xref ref-type="bibr" rid="article-141559.r25">[25]</xref><xref ref-type="bibr" rid="article-141559.r22">[22]</xref><xref ref-type="bibr" rid="article-141559.r41">[41]</xref>&#x000a0;A CT chest is recommended 3&#x000a0;to 6 months after the procedure to ensure recanalization of the occluded feeding artery did not occur. Surgery is reserved only for life-threatening hemorrhage. Similarly, lung transplantation is limited to patients with diffuse bilateral disease refractory to other treatment modalities. There is an association between oral microorganisms and PAVM-associated brain abscesses.<xref ref-type="bibr" rid="article-141559.r42">[42]</xref>&#x000a0;The pulmonary capillary bed filters small thrombi and bacteria that enter the bloodstream. Since the capillary bed is bypassed in PAVMs, a direct right-to-left shunt effectively forms, allowing paradoxical emboli to pass and cause brain abscesses or strokes.<xref ref-type="bibr" rid="article-141559.r43">[43]</xref>&#x000a0;Thus, antibiotic prophylaxis is recommended for any procedure that carries a risk of bacteremia, particularly dental procedures.&#x000a0;Finally, patients with PAVMs should be followed long-term to detect the growth of untreated PAVMs and reperfusion of treated PAVMS.</p>
        <p>
<bold>Hepatic AVMs (HAVMs)</bold>
</p>
        <p>Management of HAVMs is based on the symptoms and type of complications. HHT patients with HAVMs may have high-output cardiac failure, portal hypertension, or cirrhosis, which are managed medically. High-output cardiac failure is treated with blood transfusions for anemia, salt and fluid restriction, beta-blockers, and diuretics.&#x000a0;Intravenous bevacizumab can be considered for patients with high-output cardiac failure who fail initial management.&#x000a0;Portal hypertension and cirrhosis are treated with salt and fluid restriction, diuretics, and paracentesis.&#x000a0;Liver transplantation is reserved for those with symptomatic HAVMs who are refractory to medical management.<xref ref-type="bibr" rid="article-141559.r44">[44]</xref>&#x000a0;Finally, hepatic artery embolization should be avoided since the procedure is only temporizing and carries high morbidity and mortality.</p>
        <p>
<bold>Cerebral AVMs (CAVMs)</bold>
</p>
        <p>HHT-related CAVMs are low-grade, usually small, and cortically located with superficial venous drainage.&#x000a0;Patients symptomatic from CAVMs should be referred to a center with neurovascular expertise. The natural history of CAVMs associated with HHT is slightly more favorable than sporadic AVMs, with a yearly rupture rate of 1.3% vs. 2.2%.<xref ref-type="bibr" rid="article-141559.r45">[45]</xref><xref ref-type="bibr" rid="article-141559.r46">[46]</xref>&#x000a0;As such, conservative management should be considered for CAVMs in HHT patients. Furthermore, although there are advances in interventional therapies for CAVMs, the risks still outweigh these benefits. The ARUBA trial evaluated interventional versus medical therapy for 223 non-HHT patients with CAVMs and found the risk of stroke or death to be&#x000a0;3 times higher (30.7% vs. 10.1%) in the interventional arm.<xref ref-type="bibr" rid="article-141559.r46">[46]</xref>&#x000a0;For HHT patients with symptomatic CAVMs or risk factors, such as a family history of cerebral hemorrhage, treatment options are embolization, microsurgery, stereotactic radiation, or a combination of these modalities. Microsurgery for low-grade lesions (Spetzler-Martin grade I or II) can be effective. Spetzler-Martin grading scale estimates the risk of open surgery for cerebral AVMs. A grade 1 AVM describes a small, superficial lesion located in a non-critical area of the brain and is considered low risk for surgery. A grade 6 AVM is non-operable.<xref ref-type="bibr" rid="article-141559.r47">[47]</xref>&#x000a0;One series demonstrated a 100% obliteration rate with a 3.2% rate of neurologic deficits and 0% mortality with microsurgery.<xref ref-type="bibr" rid="article-141559.r48">[48]</xref>&#x000a0;Gamma knife surgery also has a similar risk profile with 100% obliteration rates for lesions &#x0003c; 1 mL in volume. For CAVMs that are poor surgical candidates, stereotactic radiosurgery can be considered but has a lower cure rate for larger lesions.<xref ref-type="bibr" rid="article-141559.r49">[49]</xref>&#x000a0;Embolization alone is ineffective in addressing CAVMs but could be a helpful adjunct with surgery or stereotactic radiation.</p>
      </sec>
      <sec id="article-141559.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Bleeding from diseases like von Willebrand disease or hemophilia is more generalized and occurs in an injury setting. In contrast, bleeding from HHT is more localized to the malformed blood vessels. Several diseases share similar clinical manifestations to HHT and must be ruled out during the workup. Referral to a hematologist can prove very helpful.</p>
        <p>
<bold>Limited Systemic Sclerosis</bold>
</p>
        <p>Patients with limited systemic sclerosis, called CREST syndrome, develop calcinosis, Raynaud disease, esophageal dysmotility, sclerodactyly, and telangiectasias. However, recurrent epistaxis is not a common feature of the syndrome. Specific autoantibodies may be positive in scleroderma, including anti-centromere antibodies, anti-topoisomerase I (Scl-70), and anti-RNA polymerase III.<xref ref-type="bibr" rid="article-141559.r50">[50]</xref></p>
        <p>
<bold>Ataxia-Telangiectasia</bold>
</p>
        <p>Ataxia-telangiectasia is an autosomal recessive condition that presents with cerebellar atrophy with progressive ataxia, cutaneous telangiectasias, immune defects, and increased risk for malignancies. Symptoms typically occur in the first or second decade of life. Key features of this condition include elevated serum alpha-fetoprotein (AFP) and decreased total IgG and IgA.<xref ref-type="bibr" rid="article-141559.r51">[51]</xref>&#x000a0;</p>
        <p>
<bold>Generalized Essential Telangiectasia</bold>
</p>
        <p>Generalized essential telangiectasia is rare; inherited and sporadic cases have been reported. The telangiectasias first appear on the lower extremities and slowly spread to involve the entire body.<xref ref-type="bibr" rid="article-141559.r52">[52]</xref></p>
        <p>
<bold>Hereditary Benign Telangiectasia</bold>
</p>
        <p>Hereditary benign telangiectasia is an autosomal dominant primary telangiectasia disorder with the development of telangiectasias on the skin and lips during birth or childhood. Lesions are usually asymptomatic and do not have systemic involvement. Unlike in HHT, histology of hereditary benign telangiectasia demonstrates preserved skin and dilated vessels with thicker capillary walls, explaining the lack of hemorrhage.<xref ref-type="bibr" rid="article-141559.r53">[53]</xref></p>
        <p>
<bold>Rosacea</bold>
</p>
        <p>Rosacea is a common skin disorder with recurrent facial flushing, erythema, telangiectasias, and inflammatory pustules on the face. Etiological factors for the development of the condition include genetics, environmental factors, neurovascular deregulation, and microorganisms.<xref ref-type="bibr" rid="article-141559.r54">[54]</xref>&#x000a0;See&#x000a0;<bold>Image.</bold> Ocular Telangiectasia.</p>
        <p>
<bold>Telangiectasia Macularis Eruptiva Perstans</bold>
</p>
        <p>Telangiectasia macularis eruptiva perstans is a rare form of mastocytosis. The condition is seen more frequently in adults. Telangiectatic macules manifest as flat, reddish-brown lesions on the skin due to infiltration of mast cells into the upper dermis. Systemic involvement may involve the bone marrow, GI tract, liver, and lymph.<xref ref-type="bibr" rid="article-141559.r55">[55]</xref></p>
        <p>
<bold>Dermatomyositis</bold>
</p>
        <p>Dermatomyositis is an idiopathic chronic inflammatory autoimmune disorder of the skin and muscles. Skin manifestations include heliotrope rash around the eyes, papules over digits, and periungual telangiectasias.<xref ref-type="bibr" rid="article-141559.r56">[56]</xref></p>
        <p>
<bold>Systemic Lupus Erythematosus (SLE)</bold>
</p>
        <p>Lupus erythematosus is a multi-organ autoimmune disease with varying clinical presentations. Cutaneous manifestations include a malar rash, oral and nasal ulcers, and periungual telangiectasias.<xref ref-type="bibr" rid="article-141559.r57">[57]</xref></p>
      </sec>
      <sec id="article-141559.s11" sec-type="Radiation Oncology">
        <title>Radiation Oncology</title>
        <p>As discussed above, stereotactic radiation therapy has been used to manage cerebral AVMs as a single modality or in conjunction with microsurgery or embolization for larger lesions.<xref ref-type="bibr" rid="article-141559.r58">[58]</xref>&#x000a0;Gamma knife radiosurgery offers obliteration rates of 100% for AVMs smaller than 1 mL, 85% for 1&#x000a0;to 4 mL, and 58% for lesions &#x0003e; 4 mL. The risk of symptomatic radiation necrosis directly correlates with increasing AVM size.<xref ref-type="bibr" rid="article-141559.r59">[59]</xref></p>
      </sec>
      <sec id="article-141559.s12" sec-type="Medical Oncology">
        <title>Medical Oncology</title>
        <p>Dysfunctional angiogenesis is thought to play a role in the pathogenesis of HHT, and research has focused on whether anti-angiogenic substances and immunomodulatory agents can effectively treat HHT. Bevacizumab is a humanized recombinant monoclonal antibody against vascular endothelial growth factor (VEGF), elevated in HHT. VEGF stimulates arterial, lymphatic, and venous development and suppresses endothelial cell apoptosis. Elevated VEGF levels can result in immature, abnormal vessel formation with constant remodeling.<xref ref-type="bibr" rid="article-141559.r60">[60]</xref>&#x000a0;Clinical trials and studies have explored the effectiveness of the VEGF inhibitor, administered systemically, topically, or submucosally, for control of HHT-related epistaxis.<xref ref-type="bibr" rid="article-141559.r61">[61]</xref><xref ref-type="bibr" rid="article-141559.r62">[62]</xref><xref ref-type="bibr" rid="article-141559.r63">[63]</xref><xref ref-type="bibr" rid="article-141559.r64">[64]</xref><xref ref-type="bibr" rid="article-141559.r65">[65]</xref>&#x000a0;Double-blind, randomized control trials and other comparative studies evaluating topical and intranasal submucosal bevacizumab demonstrate mixed conclusions when evaluating the severity of HHT-related epistaxis.<xref ref-type="bibr" rid="article-141559.r66">[66]</xref>&#x000a0;Two studies evaluating the submucosal application of bevacizumab demonstrated either a trend toward or significant improvement in epistaxis severity.<xref ref-type="bibr" rid="article-141559.r67">[67]</xref>&#x000a0;</p>
        <p>Primary risks associated with topical or submucosal injection of bevacizumab include septal perforation and osteonecrosis. In&#x000a0;1 clinical trial, systemic therapy with bevacizumab (5 mg/kg IV every&#x000a0;2 weeks for&#x000a0;6 treatments) demonstrated reduced epistaxis episodes and high cardiac output.<xref ref-type="bibr" rid="article-141559.r61">[61]</xref>&#x000a0;Side effects of systemic bevacizumab at oncologic doses (5&#x000a0;to 15 mg/kg) include GI perforation, hemorrhage, thromboembolism, poor wound healing, and reversible posterior leukoencephalopathy, which were not noted in the lower doses used to treat HHT. However, common adverse effects included hypertension, nausea, diarrhea, headache, and muscle or abdominal pain when used systemically. Tacrolimus, a calcineurin inhibitor used for immunosuppression, has been shown to activate the ALK1-SMAD1/5/8 pathway and improve defects due to ALK1 loss.&#x000a0;Thalidomide, an immunomodulatory imide drug, has been shown to downregulate VEGF levels in HHT, improve the integrity of vessel walls, and reduce epistaxis.<xref ref-type="bibr" rid="article-141559.r68">[68]</xref><xref ref-type="bibr" rid="article-141559.r69">[69]</xref><xref ref-type="bibr" rid="article-141559.r70">[70]</xref>&#x000a0;However, adverse effects, including neuropathy and fatigue, have limited its use as a therapeutic option.<xref ref-type="bibr" rid="article-141559.r32">[32]</xref> Studies have evaluated selective estrogen response modifiers (raloxifene, tamoxifen), progestins, and estrogens to reduce epistaxis and GI bleeding; however, findings are inconsistent.<xref ref-type="bibr" rid="article-141559.r32">[32]</xref><xref ref-type="bibr" rid="article-141559.r71">[71]</xref>&#x000a0;Furthermore, potential side effects of hormone therapy, including gynecomastia, weight gain, and venous thromboembolism, have prevented its wide use as a treatment option.&#x000a0;</p>
      </sec>
      <sec id="article-141559.s13" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The literature evaluating the overall survival and prognosis of HHT is limited but may have a shorter expected lifespan. A retrospective study demonstrated a lower median age of death in HHT versus non-HHT patients (63.2 vs. 70.0 years).<xref ref-type="bibr" rid="article-141559.r72">[72]</xref>&#x000a0;A more recent prospective study (n=675) found HHT patients to have poorer survival compared to matched controls, with a median age of death of 77 years versus 80 years.<xref ref-type="bibr" rid="article-141559.r17">[17]</xref>&#x000a0;Furthermore, the study found hazard ratios for death were highest within the first&#x000a0;3 years after HHT diagnosis and subsequently decreased. This decrease in HR could explain how HHT may be diagnosed after an acute complication such as a stroke. Early detection and screening of HHT and preventing complications could help increase life expectancy.</p>
      </sec>
      <sec id="article-141559.s14" sec-type="Complications">
        <title>Complications</title>
        <p>HHT patients have a higher risk of bleeding and neurologic complications, including anemia, cerebral abscess, stroke, venous thrombosis, and heart failure.<xref ref-type="bibr" rid="article-141559.r17">[17]</xref>&#x000a0;[Table 1]</p>
        <table-wrap id="article-141559.table0" position="float" orientation="portrait">
          <caption>
            <title>Table 1. Specific Complications Found in HHT and Recommended Prevention and Treatment</title>
          </caption>
          <table border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">
<bold>Complication</bold>
</td>
                <td rowspan="1" colspan="1">
<bold>Treatment/Prevention</bold>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Iron Deficiency</td>
                <td rowspan="1" colspan="1">Annual screen with complete blood count, ferritin,
<p>total iron-binding capacity [TIBC], and reticulocyte count</p>
Replete iron either via oral or IV when ferritin is less than 50</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Cerebral Abscess</td>
                <td rowspan="1" colspan="1">
<p>Screen and embolization of pulmonary AVMs</p>
<p>Infection prophylaxis with antibiotics before procedures</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Paradoxical Stroke</td>
                <td rowspan="1" colspan="1">
<p>Screen and embolization of pulmonary AVMs</p>
<p>Replete iron either via oral or IV when ferritin is less than 50</p>
<p>Iron deficiency seems to increase the risk of thrombotic events</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Venous Thrombosis</td>
                <td rowspan="1" colspan="1">
<p>Replete iron either via oral or IV when ferritin is less than 50</p>
<p>Iron deficiency seems to increase the risk of thrombotic events</p>
<p>Anticoagulation is not contraindicated but has been discussed&#x000a0;with specialists</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Heart Failure</td>
                <td rowspan="1" colspan="1">
<p>Check for annual brain natriuretic peptide (BNP) in the presence of</p>
<p>Hepatic AVMs</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-141559.s15" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>Scarring is a common complication after laser ablation or electrosurgical cauterization of intranasal telangiectasias due to loss of mucociliary clearance and subsequent crusting. Postoperative nasal hygiene with topical saline sprays and irrigations and deliberate postoperative debridement of crusts can prevent scarring and synechiae formation. There are no definitive guidelines for optimal postoperative management for AVMs after endovascular intervention or surgery. Postoperative care, including activity restrictions, is&#x000a0;based on the location of the AVM, size, the number of lesions, type of procedure (endovascular versus open), and extent of surgery.<xref ref-type="bibr" rid="article-141559.r73">[73]</xref>&#x000a0;Patients undergoing microsurgery for cerebral AVMs may require physical therapy after the procedure. Additional imaging may be necessary to assess the embolization site and recurrence.<xref ref-type="bibr" rid="article-141559.r74">[74]</xref></p>
      </sec>
      <sec id="article-141559.s16" sec-type="Consultations">
        <title>Consultations</title>
        <p>Since HHT affects multiple organ systems, adequate treatment requires multidisciplinary care. A referral to a hematologist is indicated to manage iron deficiency anemia and for anticoagulation if diagnosed with venous thromboembolism. Consider referring to an otolaryngologist for the management of epistaxis. A gastroenterologist should be involved if there is a concern for GI bleeds. HHT patients with pulmonary AVMs should be seen by a pulmonologist, interventional radiologist, or thoracic surgeon. The presence of a cerebral AVM warrants referral to a neurosurgeon. If embolization is not an option, an interventional radiologist or general surgeon should manage hepatic AVMs.</p>
      </sec>
      <sec id="article-141559.s17" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Affected individuals must receive education and counseling on the implications of a possible or definitive diagnosis of HHT. Given that HHT is an autosomal dominant disease, it is essential to screen family members and provide genetic counseling before conception. Early diagnosis before patients are symptomatic can allow for screening tests and interventions to be done promptly and assist in diagnosing at-risk family members.<xref ref-type="bibr" rid="article-141559.r25">[25]</xref></p>
      </sec>
      <sec id="article-141559.s18" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Early diagnosis of HHT is based on clinical findings. Genetic testing helps confirm the diagnosis but is not required for an index case unless 1) they are children who have not developed all the clinical features or 2) to test at-risk family members and identify a family-specific mutation. Screening and treatment of visceral AVMs depend on the potential for high-risk complications. For instance, proactive screening and treating asymptomatic pulmonary AVMs are encouraged compared to asymptomatic hepatic or cerebral AVMs.<xref ref-type="bibr" rid="article-141559.r25">[25]</xref></p>
      </sec>
      <sec id="article-141559.s19" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>HHT can affect multiple organ systems, and early recognition and screening for clinical manifestations and prompt interventions can decrease morbidity and mortality. Epistaxis is one of the most common presenting symptoms. Patients with HHT benefit from a multidisciplinary approach and should ideally&#x000a0;be referred to a center specializing in HHT.</p>
      </sec>
      <sec id="article-141559.s20">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=141559&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=141559">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/hereditary-hemorrhagic-telangiectasia-hht-osler-weber-rendu/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=141559">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/141559/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=141559">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-141559.s21">
        <fig id="article-141559.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Telangiectasia in Nasal Cavity. Rigid nasal endoscopy of the right nasal cavity demonstrating telangiectasias in hereditary hemorrhagic telangiectasia. Contributed by T Locke, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Stat__Pearls__HHT__nasal__endo" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-141559.s22">
        <fig id="article-141559.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Hereditary Hemorrhagic Telangiectasias on Thumb Contributed by P Chen, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="HHT__telangiectasia__thumb" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-141559.s23">
        <fig id="article-141559.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Lip Telangiectasia. The image depicts the presentation of a patient with hereditary hemorrhagic telangiectasia. Herbert L Fred, MD, Hendrik A van Dijk, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/2.0/">Public Domain</ext-link>, via Wikimedia Commons</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Case_115" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-141559.s24">
        <fig id="article-141559.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Ocular Telangiectasia. This&#x000a0;image&#x000a0;portrays the prominent ocular telangiectasia that can be seen in some people with this condition. Thomas O Crawford, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-sa/3.0/deed.en">Public Domain</ext-link>,&#x000a0;via&#x000a0;Wikimedia Commons&#x000a0;&#x000a0;</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Photo_Ocular_telangiectasia_in_a_person_with_A-T" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-141559.s25">
        <fig id="article-141559.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Telangiectasia on the Tongue. This patient has hereditary hemorrhagic telangiectasia, formerly known as Osler-Weber-Rendu syndrome, a multisystem vascular genetic disorder that produces blood vessel malformations. Contributed by RE Sumpter, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://phil.cdc.gov/QuickSearch.aspx?key=true">Public Domain</ext-link>, via&#x000a0;Public Health Image Library</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12628_lores" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-141559.s26">
        <title>References</title>
        <ref id="article-141559.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kritharis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Al-Samkari</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kuter</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective.</article-title>
            <source>Haematologica</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>103</volume>
            <issue>9</issue>
            <fpage>1433</fpage>
            <page-range>1433-1443</page-range>
            <pub-id pub-id-type="pmid">29794143</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Halderman</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sindwani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Reh</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Poetker</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Invernizzi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Marple</surname>
                <given-names>BF</given-names>
              </name>
            </person-group>
            <article-title>Medical treatment of epistaxis in hereditary hemorrhagic telangiectasia: an evidence-based review.</article-title>
            <source>Int Forum Allergy Rhinol</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>8</volume>
            <issue>6</issue>
            <fpage>713</fpage>
            <page-range>713-728</page-range>
            <pub-id pub-id-type="pmid">29393992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jackson</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Villano</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Benhammou</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pisegna</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Padua</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Gastrointestinal Manifestations of Hereditary Hemorrhagic Telangiectasia (HHT): A Systematic Review of the Literature.</article-title>
            <source>Dig Dis Sci</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>62</volume>
            <issue>10</issue>
            <fpage>2623</fpage>
            <page-range>2623-2630</page-range>
            <pub-id pub-id-type="pmid">28836046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morgan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ismail</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mao</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Madan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barnes</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hudgins</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Manning</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Intracranial hemorrhage in infants and children with hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome).</article-title>
            <source>Pediatrics</source>
            <year>2002</year>
            <month>Jan</month>
            <volume>109</volume>
            <issue>1</issue>
            <fpage>E12</fpage>
            <pub-id pub-id-type="pmid">11773580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shovlin</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Guttmacher</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Buscarini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Faughnan</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Hyland</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Westermann</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Kjeldsen</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Plauchu</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome).</article-title>
            <source>Am J Med Genet</source>
            <year>2000</year>
            <month>Mar</month>
            <day>06</day>
            <volume>91</volume>
            <issue>1</issue>
            <fpage>66</fpage>
            <page-range>66-7</page-range>
            <pub-id pub-id-type="pmid">10751092</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Govani</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Shovlin</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Hereditary haemorrhagic telangiectasia: a clinical and scientific review.</article-title>
            <source>Eur J Hum Genet</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>17</volume>
            <issue>7</issue>
            <fpage>860</fpage>
            <page-range>860-71</page-range>
            <pub-id pub-id-type="pmid">19337313</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plauchu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>de Chadar&#x000e9;vian</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Bideau</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Robert</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population.</article-title>
            <source>Am J Med Genet</source>
            <year>1989</year>
            <month>Mar</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>291</fpage>
            <page-range>291-7</page-range>
            <pub-id pub-id-type="pmid">2729347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McDonald</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wooderchak-Donahue</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>VanSant Webb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Whitehead</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Bayrak-Toydemir</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era.</article-title>
            <source>Front Genet</source>
            <year>2015</year>
            <volume>6</volume>
            <fpage>1</fpage>
            <pub-id pub-id-type="pmid">25674101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sautter</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>TL</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Hereditary Hemorrhagic Telangiectasia-Related Epistaxis.</article-title>
            <source>Otolaryngol Clin North Am</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>49</volume>
            <issue>3</issue>
            <fpage>639</fpage>
            <page-range>639-54</page-range>
            <pub-id pub-id-type="pmid">27267016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lesca</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Burnichon</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Raux</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tosi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pinson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Marion</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Babin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gilbert-Dussardier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rivi&#x000e8;re</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goizet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Faivre</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Plauchu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fr&#x000e9;bourg</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Calender</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Giraud</surname>
                <given-names>S</given-names>
              </name>
              <collab>French Rendu-Osler Network</collab>
            </person-group>
            <article-title>Distribution of ENG and ACVRL1 (ALK1) mutations in French HHT patients.</article-title>
            <source>Hum Mutat</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>598</fpage>
            <pub-id pub-id-type="pmid">16705692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lesca</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Genin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Blachier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Olivieri</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Coulet</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Brunet</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dupuis-Girod</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Buscarini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Soubrier</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Calender</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Danesino</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Giraud</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Plauchu</surname>
                <given-names>H</given-names>
              </name>
              <collab>French-Italian HHT Network</collab>
            </person-group>
            <article-title>Hereditary hemorrhagic telangiectasia: evidence for regional founder effects of ACVRL1 mutations in French and Italian patients.</article-title>
            <source>Eur J Hum Genet</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>6</issue>
            <fpage>742</fpage>
            <page-range>742-9</page-range>
            <pub-id pub-id-type="pmid">18285823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McAllister</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Grogg</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Gallione</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Baldwin</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Helmbold</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Markel</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>McKinnon</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Murrell</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1.</article-title>
            <source>Nat Genet</source>
            <year>1994</year>
            <month>Dec</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>345</fpage>
            <page-range>345-51</page-range>
            <pub-id pub-id-type="pmid">7894484</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Baldwin</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Gallione</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Marondel</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Stenzel</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Speer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pericak-Vance</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Diamond</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guttmacher</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Attisano</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kucherlapati</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Porteous</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Marchuk</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2.</article-title>
            <source>Nat Genet</source>
            <year>1996</year>
            <month>Jun</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>189</fpage>
            <page-range>189-95</page-range>
            <pub-id pub-id-type="pmid">8640225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Azuma</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Genetic and molecular pathogenesis of hereditary hemorrhagic telangiectasia.</article-title>
            <source>J Med Invest</source>
            <year>2000</year>
            <month>Aug</month>
            <volume>47</volume>
            <issue>3-4</issue>
            <fpage>81</fpage>
            <page-range>81-90</page-range>
            <pub-id pub-id-type="pmid">11019486</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gallione</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Repetto</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Legius</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rustgi</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Schelley</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Tejpar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Drouin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Westermann</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Marchuk</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4).</article-title>
            <source>Lancet</source>
            <year>2004</year>
            <month>Mar</month>
            <day>13</day>
            <volume>363</volume>
            <issue>9412</issue>
            <fpage>852</fpage>
            <page-range>852-9</page-range>
            <pub-id pub-id-type="pmid">15031030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Donaldson</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>McKeever</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>IP</given-names>
              </name>
              <name>
                <surname>Hubbard</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Fogarty</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>The UK prevalence of hereditary haemorrhagic telangiectasia and its association with sex, socioeconomic status and region of residence: a population-based study.</article-title>
            <source>Thorax</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>69</volume>
            <issue>2</issue>
            <fpage>161</fpage>
            <page-range>161-7</page-range>
            <pub-id pub-id-type="pmid">24188926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Donaldson</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>McKeever</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>IP</given-names>
              </name>
              <name>
                <surname>Hubbard</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Fogarty</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>Complications and mortality in hereditary hemorrhagic telangiectasia: A population-based study.</article-title>
            <source>Neurology</source>
            <year>2015</year>
            <month>May</month>
            <day>05</day>
            <volume>84</volume>
            <issue>18</issue>
            <fpage>1886</fpage>
            <page-range>1886-93</page-range>
            <pub-id pub-id-type="pmid">25862798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fern&#x000e1;ndez-L</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sanz-Rodriguez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Blanco</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Bernab&#x000e9;u</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Botella</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Hereditary hemorrhagic telangiectasia, a vascular dysplasia affecting the TGF-beta signaling pathway.</article-title>
            <source>Clin Med Res</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>66</fpage>
            <page-range>66-78</page-range>
            <pub-id pub-id-type="pmid">16595794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grigg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Earnshaw</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and Treatment of Hereditary Hemorrhagic Telangiectasia.</article-title>
            <source>Ochsner J</source>
            <year>2017</year>
            <season>Summer</season>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>157</fpage>
            <page-range>157-161</page-range>
            <pub-id pub-id-type="pmid">28638289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dupuis-Girod</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bailly</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Plauchu</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Hereditary hemorrhagic telangiectasia: from molecular biology to patient care.</article-title>
            <source>J Thromb Haemost</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>8</volume>
            <issue>7</issue>
            <fpage>1447</fpage>
            <page-range>1447-56</page-range>
            <pub-id pub-id-type="pmid">20345718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duncan</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Kneebone</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Chi</surname>
                <given-names>EY</given-names>
              </name>
              <name>
                <surname>Hraska</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Isik</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Rosenthal</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Starnes</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Lupinetti</surname>
                <given-names>FM</given-names>
              </name>
            </person-group>
            <article-title>A detailed histologic analysis of pulmonary arteriovenous malformations in children with cyanotic congenital heart disease.</article-title>
            <source>J Thorac Cardiovasc Surg</source>
            <year>1999</year>
            <month>May</month>
            <volume>117</volume>
            <issue>5</issue>
            <fpage>931</fpage>
            <page-range>931-8</page-range>
            <pub-id pub-id-type="pmid">10220688</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Faughnan</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Mager</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Hetts</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Palda</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Lang-Robertson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Buscarini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Deslandres</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kasthuri</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Lausman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Poetker</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ratjen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chesnutt</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Clancy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Whitehead</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Al-Samkari</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chakinala</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Conrad</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cortes</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Crocione</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Darling</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Gussem</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Derksen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dupuis-Girod</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Foy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Geisthoff</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Gossage</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Hammill</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Heimdal</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Iyer</surname>
                <given-names>VN</given-names>
              </name>
              <name>
                <surname>Kjeldsen</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Komiyama</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Korenblatt</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McMahon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McWilliams</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Meek</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Mei-Zahav</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Olitsky</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pantalone</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Piccirillo</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Plahn</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Porteous</surname>
                <given-names>MEM</given-names>
              </name>
              <name>
                <surname>Post</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Radovanovic</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Rochon</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Rodriguez-Lopez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sabba</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Serra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shovlin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sprecher</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Winship</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Zarrabeitia</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia.</article-title>
            <source>Ann Intern Med</source>
            <year>2020</year>
            <month>Dec</month>
            <day>15</day>
            <volume>173</volume>
            <issue>12</issue>
            <fpage>989</fpage>
            <page-range>989-1001</page-range>
            <pub-id pub-id-type="pmid">32894695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>AAssar</surname>
                <given-names>OS</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>RI</given-names>
              </name>
            </person-group>
            <article-title>The natural history of epistaxis in hereditary hemorrhagic telangiectasia.</article-title>
            <source>Laryngoscope</source>
            <year>1991</year>
            <month>Sep</month>
            <volume>101</volume>
            <issue>9</issue>
            <fpage>977</fpage>
            <page-range>977-80</page-range>
            <pub-id pub-id-type="pmid">1886446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shovlin</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Bamford</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Ramadan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kulinskaya</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Primary determinants of ischaemic stroke/brain abscess risks are independent of severity of pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia.</article-title>
            <source>Thorax</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>63</volume>
            <issue>3</issue>
            <fpage>259</fpage>
            <page-range>259-66</page-range>
            <pub-id pub-id-type="pmid">17981912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garg</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Khunger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Optimal management of hereditary hemorrhagic telangiectasia.</article-title>
            <source>J Blood Med</source>
            <year>2014</year>
            <volume>5</volume>
            <fpage>191</fpage>
            <page-range>191-206</page-range>
            <pub-id pub-id-type="pmid">25342923</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shovlin</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Tuddenham</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Temperley</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Perembelon</surname>
                <given-names>YF</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Seidman</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Seidman</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>A gene for hereditary haemorrhagic telangiectasia maps to chromosome 9q3.</article-title>
            <source>Nat Genet</source>
            <year>1994</year>
            <month>Feb</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>205</fpage>
            <page-range>205-9</page-range>
            <pub-id pub-id-type="pmid">8162076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pahl</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Choudhury</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wusik</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hammill</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pollak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kasthuri</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Applicability of the Cura&#x000e7;ao Criteria for the Diagnosis of Hereditary Hemorrhagic Telangiectasia in the Pediatric Population.</article-title>
            <source>J Pediatr</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>197</volume>
            <fpage>207</fpage>
            <page-range>207-213</page-range>
            <pub-id pub-id-type="pmid">29655863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bharatha</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Faughnan</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pourmohamad</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Krings</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bayrak-Toydemir</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pawlikowska</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>McCulloch</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Lawton</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Dowd</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Terbrugge</surname>
                <given-names>KG</given-names>
              </name>
            </person-group>
            <article-title>Brain arteriovenous malformation multiplicity predicts the diagnosis of hereditary hemorrhagic telangiectasia: quantitative assessment.</article-title>
            <source>Stroke</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>72</fpage>
            <page-range>72-8</page-range>
            <pub-id pub-id-type="pmid">22034007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shovlin</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Sodhi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lasjaunias</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Sheppard</surname>
                <given-names>MN</given-names>
              </name>
            </person-group>
            <article-title>Estimates of maternal risks of pregnancy for women with hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): suggested approach for obstetric services.</article-title>
            <source>BJOG</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>115</volume>
            <issue>9</issue>
            <fpage>1108</fpage>
            <page-range>1108-15</page-range>
            <pub-id pub-id-type="pmid">18518871</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tunkel</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Anne</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Payne</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Ishman</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Abramson</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Alikhaani</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Benoit</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Bercovitz</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Chernobilsky</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Feldstein</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Hackell</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Holbrook</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Holdsworth</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Lind</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Poetker</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Riley</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Seidman</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Vadlamudi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Valdez</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Nnacheta</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Monjur</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>Clinical Practice Guideline: Nosebleed (Epistaxis).</article-title>
            <source>Otolaryngol Head Neck Surg</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>162</volume>
            <issue>1_suppl</issue>
            <fpage>S1</fpage>
            <page-range>S1-S38</page-range>
            <pub-id pub-id-type="pmid">31910111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yaniv</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Preis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shevro</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nageris</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hadar</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Anti-estrogen therapy for hereditary hemorrhagic telangiectasia - a long-term clinical trial.</article-title>
            <source>Rhinology</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>49</volume>
            <issue>2</issue>
            <fpage>214</fpage>
            <page-range>214-6</page-range>
            <pub-id pub-id-type="pmid">21743879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Samkari</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of care.</article-title>
            <source>Blood</source>
            <year>2021</year>
            <month>Feb</month>
            <day>18</day>
            <volume>137</volume>
            <issue>7</issue>
            <fpage>888</fpage>
            <page-range>888-895</page-range>
            <pub-id pub-id-type="pmid">33171488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gaillard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dupuis-Girod</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boutitie</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rivi&#x000e8;re</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Morini&#x000e8;re</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hatron</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Manfredi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kaminsky</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Capitaine</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Roy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gueyffier</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Plauchu</surname>
                <given-names>H</given-names>
              </name>
              <collab>ATERO Study Group</collab>
            </person-group>
            <article-title>Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease.</article-title>
            <source>J Thromb Haemost</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>12</volume>
            <issue>9</issue>
            <fpage>1494</fpage>
            <page-range>1494-502</page-range>
            <pub-id pub-id-type="pmid">25040799</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Geisthoff</surname>
                <given-names>UW</given-names>
              </name>
              <name>
                <surname>Seyfert</surname>
                <given-names>UT</given-names>
              </name>
              <name>
                <surname>K&#x000fc;bler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bieg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Plinkert</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>K&#x000f6;nig</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study.</article-title>
            <source>Thromb Res</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>134</volume>
            <issue>3</issue>
            <fpage>565</fpage>
            <page-range>565-71</page-range>
            <pub-id pub-id-type="pmid">25005464</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boyer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fernandes</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yueh</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Prospective randomized trial of sclerotherapy vs standard treatment for epistaxis due to hereditary hemorrhagic telangiectasia.</article-title>
            <source>Int Forum Allergy Rhinol</source>
            <year>2015</year>
            <month>May</month>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>435</fpage>
            <page-range>435-40</page-range>
            <pub-id pub-id-type="pmid">25643928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuan</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Sinonasal quality of life outcomes following laser treatment of epistaxis related to hereditary hemorrhagic telangiectasia.</article-title>
            <source>Lasers Med Sci</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>527</fpage>
            <page-range>527-531</page-range>
            <pub-id pub-id-type="pmid">28116537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lund</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Darby</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rimmer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Amin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Husain</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Nasal closure for severe hereditary haemorrhagic telangiectasia in 100 patients. The Lund modification of the Young's procedure: a 22-year experience.</article-title>
            <source>Rhinology</source>
            <year>2017</year>
            <month>Jun</month>
            <day>01</day>
            <volume>55</volume>
            <issue>2</issue>
            <fpage>135</fpage>
            <page-range>135-141</page-range>
            <pub-id pub-id-type="pmid">28064338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peyrin-Biroulet</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Williet</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cacoub</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review.</article-title>
            <source>Am J Clin Nutr</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>102</volume>
            <issue>6</issue>
            <fpage>1585</fpage>
            <page-range>1585-94</page-range>
            <pub-id pub-id-type="pmid">26561626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edwards</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Shehata</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Faughnan</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Hereditary hemorrhagic telangiectasia patients can tolerate anticoagulation.</article-title>
            <source>Ann Hematol</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>91</volume>
            <issue>12</issue>
            <fpage>1959</fpage>
            <page-range>1959-68</page-range>
            <pub-id pub-id-type="pmid">23053175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shovlin</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Millar</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Droege</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kjeldsen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Manfredi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Suppressa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ugolini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Coote</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fialla</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Geisthoff</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Lenato</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Mager</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Pagella</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Post</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Sabb&#x000e0;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sure</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Torring</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Dupuis-Girod</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Buscarini</surname>
                <given-names>E</given-names>
              </name>
              <collab>VASCERN-HHT</collab>
            </person-group>
            <article-title>Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2019</year>
            <month>Aug</month>
            <day>28</day>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>210</fpage>
            <pub-id pub-id-type="pmid">31462308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Faughnan</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Palda</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Garcia-Tsao</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Geisthoff</surname>
                <given-names>UW</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Proctor</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Spears</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Buscarini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chesnutt</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Cottin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ganguly</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gossage</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Guttmacher</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Hyland</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Kennedy</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Korzenik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mager</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Ozanne</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Piccirillo</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Picus</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Plauchu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Porteous</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Pyeritz</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Sabba</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Swanson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Terry</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Westermann</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Zarrabeitia</surname>
                <given-names>R</given-names>
              </name>
              <collab>HHT Foundation International - Guidelines Working Group</collab>
            </person-group>
            <article-title>International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia.</article-title>
            <source>J Med Genet</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>48</volume>
            <issue>2</issue>
            <fpage>73</fpage>
            <page-range>73-87</page-range>
            <pub-id pub-id-type="pmid">19553198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shovlin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bamford</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wray</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Post-NICE 2008: Antibiotic prophylaxis prior to dental procedures for patients with pulmonary arteriovenous malformations (PAVMs) and hereditary haemorrhagic telangiectasia.</article-title>
            <source>Br Dent J</source>
            <year>2008</year>
            <month>Nov</month>
            <day>22</day>
            <volume>205</volume>
            <issue>10</issue>
            <fpage>531</fpage>
            <page-range>531-3</page-range>
            <pub-id pub-id-type="pmid">19023305</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nam</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Kwon</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Brain Abscesses Associated with Asymptomatic Pulmonary Arteriovenous Fistulas.</article-title>
            <source>J Korean Neurosurg Soc</source>
            <year>2017</year>
            <month>Jan</month>
            <day>01</day>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>118</fpage>
            <page-range>118-124</page-range>
            <pub-id pub-id-type="pmid">28061502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lerut</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Orlando</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Adam</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sabb&#x000e0;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pfitzmann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Klempnauer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Belghiti</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pirenne</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thevenot</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hillert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Gonze</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Karam</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Boillot</surname>
                <given-names>O</given-names>
              </name>
              <collab>European Liver Transplant Association</collab>
            </person-group>
            <article-title>Liver transplantation for hereditary hemorrhagic telangiectasia: Report of the European liver transplant registry.</article-title>
            <source>Ann Surg</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>244</volume>
            <issue>6</issue>
            <fpage>854</fpage>
            <page-range>854-62; discussion 862-4</page-range>
            <pub-id pub-id-type="pmid">17122610</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hung</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Braileanu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Caplan</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Colby</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Coon</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Tamargo</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Lower Risk of Intracranial Arteriovenous Malformation Hemorrhage in Patients With Hereditary Hemorrhagic Telangiectasia.</article-title>
            <source>Neurosurgery</source>
            <year>2016</year>
            <month>May</month>
            <volume>78</volume>
            <issue>5</issue>
            <fpage>684</fpage>
            <page-range>684-93</page-range>
            <pub-id pub-id-type="pmid">26540357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohr</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Parides</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Stapf</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Moquete</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Moy</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Overbey</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Al-Shahi Salman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vicaut</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Houdart</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cordonnier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stefani</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Hartmann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>von Kummer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Biondi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berkefeld</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Klijn</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Harkness</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Libman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Barreau</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Moskowitz</surname>
                <given-names>AJ</given-names>
              </name>
              <collab>international ARUBA investigators</collab>
            </person-group>
            <article-title>Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial.</article-title>
            <source>Lancet</source>
            <year>2014</year>
            <month>Feb</month>
            <day>15</day>
            <volume>383</volume>
            <issue>9917</issue>
            <fpage>614</fpage>
            <page-range>614-21</page-range>
            <pub-id pub-id-type="pmid">24268105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spetzler</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>A proposed grading system for arteriovenous malformations.</article-title>
            <source>J Neurosurg</source>
            <year>1986</year>
            <month>Oct</month>
            <volume>65</volume>
            <issue>4</issue>
            <fpage>476</fpage>
            <page-range>476-83</page-range>
            <pub-id pub-id-type="pmid">3760956</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schramm</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schaller</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Esche</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bostr&#x000f6;m</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Microsurgery for cerebral arteriovenous malformations: subgroup outcomes in a consecutive series of 288 cases.</article-title>
            <source>J Neurosurg</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>126</volume>
            <issue>4</issue>
            <fpage>1056</fpage>
            <page-range>1056-1063</page-range>
            <pub-id pub-id-type="pmid">27285541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lunsford</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Niranjan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kondziolka</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sirin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Flickinger</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Arteriovenous malformation radiosurgery: a twenty year perspective.</article-title>
            <source>Clin Neurosurg</source>
            <year>2008</year>
            <volume>55</volume>
            <fpage>108</fpage>
            <page-range>108-19</page-range>
            <pub-id pub-id-type="pmid">19248675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r50">
          <label>50</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Adigun</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hariz</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Systemic Sclerosis (Scleroderma)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>4</month>
            <day>5</day>
            <pub-id pub-id-type="pmid">28613625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r51">
          <label>51</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Riboldi</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Samanta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Asuncion</surname>
                <given-names>RMD</given-names>
              </name>
              <name>
                <surname>Frucht</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Ataxia-Telangiectasia</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>3</month>
            <day>6</day>
            <pub-id pub-id-type="pmid">30137827</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blume</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Generalized essential telangiectasia: a case report and review of the literature.</article-title>
            <source>Cutis</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>75</volume>
            <issue>4</issue>
            <fpage>223</fpage>
            <page-range>223-4</page-range>
            <pub-id pub-id-type="pmid">15916219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rebellato</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Martins</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Stella</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Tokarski</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>A case of benign hereditary telangiectasia without family history.</article-title>
            <source>An Bras Dermatol</source>
            <year>2017</year>
            <season>Jan-Feb</season>
            <volume>92</volume>
            <issue>1</issue>
            <fpage>162</fpage>
            <page-range>162-163</page-range>
            <pub-id pub-id-type="pmid">28225986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r54">
          <label>54</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Farshchian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Daveluy</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Rosacea</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">32491506</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Costa</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Moura</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Rodrigues</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pineiro-Maceira</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ramos-E-Silva</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Telangiectasia macularis eruptiva perstans: a rare form of adult mastocytosis.</article-title>
            <source>J Clin Aesthet Dermatol</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>4</volume>
            <issue>10</issue>
            <fpage>52</fpage>
            <page-range>52-4</page-range>
            <pub-id pub-id-type="pmid">22010057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Callen</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Wortmann</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Dermatomyositis.</article-title>
            <source>Clin Dermatol</source>
            <year>2006</year>
            <season>Sep-Oct</season>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>363</fpage>
            <page-range>363-73</page-range>
            <pub-id pub-id-type="pmid">16966018</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r57">
          <label>57</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Justiz Vaillant</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Varacallo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Systemic Lupus Erythematosus</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">30571026</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gamboa</surname>
                <given-names>NT</given-names>
              </name>
              <name>
                <surname>Joyce</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Eli</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Taussky</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Whitehead</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Kalani</surname>
                <given-names>MYS</given-names>
              </name>
            </person-group>
            <article-title>Clinical presentation and treatment paradigms of brain arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia.</article-title>
            <source>J Clin Neurosci</source>
            <year>2018</year>
            <month>May</month>
            <volume>51</volume>
            <fpage>22</fpage>
            <page-range>22-28</page-range>
            <pub-id pub-id-type="pmid">29483005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woodall</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Nakaji</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Spetzler</surname>
                <given-names>RF</given-names>
              </name>
            </person-group>
            <article-title>Benefits of Treating Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia: A Retrospective Analysis of 14 Patients.</article-title>
            <source>World Neurosurg X</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>3</volume>
            <fpage>100029</fpage>
            <pub-id pub-id-type="pmid">31225521</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arizmendez</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Rudmik</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Poetker</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Intravenous bevacizumab for complications of hereditary hemorrhagic telangiectasia: a review of the literature.</article-title>
            <source>Int Forum Allergy Rhinol</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>5</volume>
            <issue>11</issue>
            <fpage>1042</fpage>
            <page-range>1042-7</page-range>
            <pub-id pub-id-type="pmid">26202958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dupuis-Girod</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ginon</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Saurin</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Marion</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Guillot</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Decullier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Roux</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carette</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Gilbert-Dussardier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hatron</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Lacombe</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lorcerie</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rivi&#x000e8;re</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Corre</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Giraud</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bailly</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Paintaud</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ternant</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Valette</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Plauchu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Faure</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.</article-title>
            <source>JAMA</source>
            <year>2012</year>
            <month>Mar</month>
            <day>07</day>
            <volume>307</volume>
            <issue>9</issue>
            <fpage>948</fpage>
            <page-range>948-55</page-range>
            <pub-id pub-id-type="pmid">22396517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dupuis-Girod</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ambrun</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Decullier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Samson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Roux</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fargeton</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Rioufol</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schwiertz</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Disant</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chapuis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Donazzolo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Paintaud</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Edery</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Faure</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>ELLIPSE Study: a Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia.</article-title>
            <source>MAbs</source>
            <year>2014</year>
            <season>May-Jun</season>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>794</fpage>
            <page-range>794-9</page-range>
            <pub-id pub-id-type="pmid">24481211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riss</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Burian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kranebitter</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kaider</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arnoldner</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial.</article-title>
            <source>Head Neck</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>37</volume>
            <issue>6</issue>
            <fpage>783</fpage>
            <page-range>783-7</page-range>
            <pub-id pub-id-type="pmid">24595923</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karnezis</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy.</article-title>
            <source>Laryngoscope</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>122</volume>
            <issue>3</issue>
            <fpage>495</fpage>
            <page-range>495-7</page-range>
            <pub-id pub-id-type="pmid">22147664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stokes</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rimmer</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Intranasal bevacizumab in the treatment of HHT -related epistaxis: a systematic review.</article-title>
            <source>Rhinology</source>
            <year>2018</year>
            <month>Mar</month>
            <day>01</day>
            <volume>56</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-10</page-range>
            <pub-id pub-id-type="pmid">29166422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guldmann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dupret</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nivoix</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Schultz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Debry</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Bevacizumab nasal spray: Noninvasive treatment of epistaxis in patients with Rendu-Osler disease.</article-title>
            <source>Laryngoscope</source>
            <year>2012</year>
            <month>May</month>
            <volume>122</volume>
            <issue>5</issue>
            <fpage>953</fpage>
            <page-range>953-5</page-range>
            <pub-id pub-id-type="pmid">22447341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dheyauldeen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>&#x000d8;stertun Geirdal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Osnes</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vartdal</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Dollner</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose.</article-title>
            <source>Laryngoscope</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>122</volume>
            <issue>6</issue>
            <fpage>1210</fpage>
            <page-range>1210-4</page-range>
            <pub-id pub-id-type="pmid">22565282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Invernizzi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Quaglia</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Klersy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pagella</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ornati</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Matti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Spinozzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Plumitallo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grignani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Olivieri</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bastia</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bellistri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Danesino</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Benazzo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Balduini</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study.</article-title>
            <source>Lancet Haematol</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>2</volume>
            <issue>11</issue>
            <fpage>e465</fpage>
            <page-range>e465-73</page-range>
            <pub-id pub-id-type="pmid">26686256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lebrin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Srun</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Raymond</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>van den Brink</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Freitas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Br&#x000e9;ant</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mathivet</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Larriv&#x000e9;e</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Arthur</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Westermann</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Disch</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mager</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Snijder</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Eichmann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mummery</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia.</article-title>
            <source>Nat Med</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>420</fpage>
            <page-range>420-8</page-range>
            <pub-id pub-id-type="pmid">20364125</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hosman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Westermann</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Snijder</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Disch</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mummery</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Mager</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Follow-up of Thalidomide treatment in patients with Hereditary Haemorrhagic Telangiectasia.</article-title>
            <source>Rhinology</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>53</volume>
            <issue>4</issue>
            <fpage>340</fpage>
            <page-range>340-4</page-range>
            <pub-id pub-id-type="pmid">26735132</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jameson</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Cave</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Hormonal and antihormonal therapy for epistaxis in hereditary hemorrhagic telangiectasia.</article-title>
            <source>Laryngoscope</source>
            <year>2004</year>
            <month>Apr</month>
            <volume>114</volume>
            <issue>4</issue>
            <fpage>705</fpage>
            <page-range>705-9</page-range>
            <pub-id pub-id-type="pmid">15064628</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sabb&#x000e0;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pasculli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Suppressa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>D'Ovidio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lenato</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Resta</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Assennato</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Guanti</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Life expectancy in patients with hereditary haemorrhagic telangiectasia.</article-title>
            <source>QJM</source>
            <year>2006</year>
            <month>May</month>
            <volume>99</volume>
            <issue>5</issue>
            <fpage>327</fpage>
            <page-range>327-34</page-range>
            <pub-id pub-id-type="pmid">16595564</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trerotola</surname>
                <given-names>SO</given-names>
              </name>
              <name>
                <surname>Pyeritz</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>PAVM embolization: an update.</article-title>
            <source>AJR Am J Roentgenol</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>195</volume>
            <issue>4</issue>
            <fpage>837</fpage>
            <page-range>837-45</page-range>
            <pub-id pub-id-type="pmid">20858807</pub-id>
          </element-citation>
        </ref>
        <ref id="article-141559.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chamarthy</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sutphin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lamus</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Saboo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kalva</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary arteriovenous malformations: endovascular therapy.</article-title>
            <source>Cardiovasc Diagn Ther</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>338</fpage>
            <page-range>338-349</page-range>
            <pub-id pub-id-type="pmid">30057880</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
